ClinicalTrials.gg
CompletedNCT00139880Updated Sep 4, 2013

A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

A Phase 3 interventional study of Parcopa in Parkinson's Disease, sponsored by UCB Pharma. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-09-04.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Parkinson Disease by UCB S.A. — none open to participants now, none under way, none of them phase 3. Parkinson Disease · UCB S.A..

Started
2005
with 1 other
Phase 3
19 of 44
none open now
Registered
1st of 44
by date

Among the 44 studies in Parkinson Disease by UCB S.A., this one is one of 2 that started in 2005, is one of 19 in phase 3, and was the 1st registered.

Parkinson Disease

4,576 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 44 studies in Parkinson Disease by UCB S.A. is open now. The open studies under Parkinson Disease, anywhere →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies in Parkinson Disease by UCB S.A. as a file.
02

Study summary

To test whether Parcopa, a new Orally Disintegrating Tablet of Carbidopa-Levodopa, has a faster onset of action, changes in the UPDRS Motor Exam score at intervals after a single dose of Parcopa or Sinemet are being compared in 10 subjects with Parkinson's disease. Subjects 40 years or older having idiopathic PD with Hoehn and Yahr state II or III are eligible if taking a stable dose of \< 200 mg carbidopa and \< 2000 mg levodopa daily. At both treatment visits, either Parcopa or Sinemet, plus a placebo of the opposite tablet (ODT or conventional) are administered. The dose is the same as the subject's prestudy regimen. The primary efficacy variable, time to onset of action, is the first postdose time when a 30% decrease (30% improvement) in the total score is achieved. All UPDRS evaluations are done by a rater blinded to the active treatment received by the subject.

Read the detailed description

See approved Package Insert for Adverse Event information.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable Parkinson's disease

Exclusion criteria

Exclusion Criteria:

  • idiopathic PD with Hoehn and Yahr state II or III
05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double

Interventions

  • DrugParcopa
06

Study locations

1 site
  • Schwarz
    Milwaukee, Wisconsin, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Aug 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Aug 31, 2005
Start
Jun 2005
Primary completionActual
Aug 2005
CompletionActual
Aug 2005
Last update
Sep 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00139880
Lead sponsor
UCB Pharma
First posted
Aug 31, 2005
Start date
Jun 2005
Primary completion
Aug 2005
Completion
Aug 2005
Last update
Sep 4, 2013

Study contacts

UCB Clinical Trial Call Center
study director · UCB Pharma
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion